|
Name |
Perinadine A
|
Molecular Formula | C28H37NO7 | |
IUPAC Name* |
(6S,7R,9S,10S,14R)-3-hydroxy-4,6,7-trimethyl-13-[(E)-2-methyl-3-oxodec-8-enoyl]-8,15-dioxa-13-azatetracyclo[7.6.1.05,16.010,14]hexadeca-1(16),2,4-triene-2-carboxylic acid
|
|
SMILES |
C/C=C/CCCCC(=O)C(C)C(=O)N1CC[C@@H]2[C@H]1OC3=C4[C@H]2O[C@@H]([C@H](C4=C(C(=C3C(=O)O)O)C)C)C
|
|
InChI |
InChI=1S/C28H37NO7/c1-6-7-8-9-10-11-19(30)15(3)26(32)29-13-12-18-24-21-20(14(2)17(5)35-24)16(4)23(31)22(28(33)34)25(21)36-27(18)29/h6-7,14-15,17-18,24,27,31H,8-13H2,1-5H3,(H,33,34)/b7-6+/t14-,15?,17-,18+,24+,27-/m1/s1
|
|
InChIKey |
SUQZYGYUFVUJGV-DIPCPZNJSA-N
|
|
Synonyms |
Perinadine A; (6S,7R,9S,10S,14R)-3-Hydroxy-4,6,7-trimethyl-13-[(E)-2-methyl-3-oxodec-8-enoyl]-8,15-dioxa-13-azatetracyclo[7.6.1.05,16.010,14]hexadeca-1(16),2,4-triene-2-carboxylic acid
|
|
CAS | NA | |
PubChem CID | 11598520 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 499.6 | ALogp: | 4.9 |
HBD: | 2 | HBA: | 7 |
Rotatable Bonds: | 8 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 113.0 | Aromatic Rings: | 4 |
Heavy Atoms: | 36 | QED Weighted: | 0.285 |
Caco-2 Permeability: | -5.385 | MDCK Permeability: | 0.00002060 |
Pgp-inhibitor: | 0.472 | Pgp-substrate: | 0.388 |
Human Intestinal Absorption (HIA): | 0.031 | 20% Bioavailability (F20%): | 0.014 |
30% Bioavailability (F30%): | 0.032 |
Blood-Brain-Barrier Penetration (BBB): | 0.055 | Plasma Protein Binding (PPB): | 99.90% |
Volume Distribution (VD): | 0.527 | Fu: | 1.66% |
CYP1A2-inhibitor: | 0.022 | CYP1A2-substrate: | 0.122 |
CYP2C19-inhibitor: | 0.042 | CYP2C19-substrate: | 0.497 |
CYP2C9-inhibitor: | 0.226 | CYP2C9-substrate: | 0.863 |
CYP2D6-inhibitor: | 0.035 | CYP2D6-substrate: | 0.133 |
CYP3A4-inhibitor: | 0.382 | CYP3A4-substrate: | 0.157 |
Clearance (CL): | 1.393 | Half-life (T1/2): | 0.431 |
hERG Blockers: | 0.012 | Human Hepatotoxicity (H-HT): | 0.734 |
Drug-inuced Liver Injury (DILI): | 0.974 | AMES Toxicity: | 0.011 |
Rat Oral Acute Toxicity: | 0.8 | Maximum Recommended Daily Dose: | 0.275 |
Skin Sensitization: | 0.11 | Carcinogencity: | 0.356 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.009 |
Respiratory Toxicity: | 0.06 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC005202 | 0.403 | D0O5FY | 0.219 | ||||
ENC000945 | 0.313 | D0WY9N | 0.208 | ||||
ENC006017 | 0.282 | D0H2YX | 0.207 | ||||
ENC005296 | 0.282 | D0Q1MS | 0.205 | ||||
ENC002792 | 0.263 | D03JSJ | 0.205 | ||||
ENC006018 | 0.263 | D07UWV | 0.205 | ||||
ENC004086 | 0.253 | D0U5CE | 0.205 | ||||
ENC003668 | 0.252 | D03LGG | 0.205 | ||||
ENC006016 | 0.248 | D07IPB | 0.204 | ||||
ENC001023 | 0.245 | D04FBR | 0.201 |